Lantheus director James Thrall sells $94,760 in stock

Published 17/01/2025, 22:18
Lantheus director James Thrall sells $94,760 in stock

In a recent transaction, James H. Thrall, a director at Lantheus (NASDAQ:LNTH) Holdings, Inc. (NASDAQ:LNTH), sold 1,000 shares of the company's common stock. The shares were sold at a price of $94.76 each, totaling $94,760. Following this transaction, Thrall now holds 33,207 shares of Lantheus Holdings. The sale was conducted under a Rule 10b5-1 trading plan, which was adopted by Thrall on May 21, 2024.The $6.37 billion medical imaging company has demonstrated strong performance, with a 65.7% return over the past year and an EXCELLENT financial health rating according to InvestingPro analysis. Trading at a P/E of 14.8, InvestingPro's Fair Value analysis indicates the stock is currently undervalued. For comprehensive insider trading analysis and 8 additional key insights about LNTH, investors can access the full Pro Research Report on InvestingPro.

In other recent news, Lantheus Holdings has made significant strides in its financial restructuring, expanding its credit line from $350 million to $750 million and extending the maturity date from 2027 to 2029. The company reported an 18.4% increase in consolidated net revenue for Q3 2024, largely driven by the sales of PYLARIFY and DEFINITY. Lantheus has adjusted its full-year 2024 revenue guidance to a range of $1.51 billion to $1.52 billion, and its fully-diluted earnings per share forecast to between $6.65 and $6.70.

In terms of leadership, Dr. Jeff Humphrey is stepping down as Chief Medical (TASE:PMCN) Officer, with CEO Brian Markison and President Paul Blanchfield assuming interim responsibilities. Analyst firms including Goldman Sachs, TD Cowen, and Leerink Partners have provided their perspectives on Lantheus, with ratings ranging from Buy to Outperform and price targets between $110 and $143.

These developments highlight Lantheus Holdings' ongoing efforts to strengthen its financial position, operational efficiency, and market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.